Medication info
HURESTO Tablet 10 mg (Rosuvastatin Calcium)

HURESTO Tablet 10 mg (Rosuvastatin Calcium)

Prescription medicationTabletOral
Ingredient · strength
Rosuvastatin Calcium›10.4mg / 1 tablet
Manufacturer / importer
Hubist Pharmaceutical Co., Ltd.
Appearance
Pink, round film-coated tablets
Packaging
30 tablets (15 tablets/PTP x 2), 30 tablets/bottle, 100 tablets/bottle
Approval status
Active

MFDS item code 201404929 · Approved 2014.10.27 · Insurance code 628800370

Summary

Main use
Treatment of dyslipidemia, inhibition of atherosclerosis progression, and prevention of cardiovascular disease
Who takes it
Adults · Children
Adult dose
1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily; if a greater reduction in LDL cholesterol is required, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which is adequate for most patients. The maintenance dose should be adjusted appropriately at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and patient response, and may be increased to a maximum of 20 milligrams per day. 3. Elderly patients: No dose adjustment is necessary. 4. Patients with renal impairment: No dose adjustment is necessary for patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering this medicine at 20mg to patients with moderate renal impairment. 5. Patients with hepatic impairment: Systemic exposure to rosuvastatin did not increase in patients with a Child-Pugh score of 7 or less, but increased in patients with a Child-Pugh score of 8 or 9. Renal function tests should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score above 9. Do not administer this medicine to patients with active liver disease. 6. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40 milligram dose is contraindicated. 7. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40 milligram dose is contraindicated in some of these patients.
Child dose
Ages 10 to 17 years: The usual dose range is 5 milligrams to 20 milligrams once daily. (There are no clinical data on doses higher than 20 milligrams in pediatric patients.) The dose should be adjusted individually according to the recommended treatment goal for each patient. The dose should be adjusted at intervals of 4 weeks or longer. Under 10 years of age: Safety and efficacy have not been established.

Ingredients

Manufacturer
Hubist Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of dyslipidemia, inhibition of atherosclerosis progression, and prevention of cardiovascular disease

  • Primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed dyslipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • primary dysbetalipoproteinemia
  • coronary heart disease
  • increased high-sensitivity C-reactive protein
  • hypertension
  • low HDL-cholesterol levels
  • smoking
View approved original text

This medication is used as an adjunct therapy for patients with primary hypercholesterolemia and mixed dyslipidemia when diet and exercise are inadequate. It is administered in conjunction with diet or other lipid-lowering therapies for patients with homozygous familial hypercholesterolemia. It effectively lowers total cholesterol and LDL-cholesterol levels in patients with hypercholesterolemia, delaying the progression of atherosclerosis. It can also be administered as an adjunct to diet in pediatric patients aged 10 to 17 with heterozygous familial hypercholesterolemia. Furthermore, it helps dietary management in patients with dysbetalipoproteinemia and reduces the risk of stroke, myocardial infarction, and restenosis in men over 50 years of age and women over 60 years of age with specific cardiovascular risk factors. Hence, this medication is used to reduce the risk of dyslipidemia and related cardiovascular disease and to improve symptoms.

How to take

Adult dose

1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily; if a greater reduction in LDL cholesterol is required, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which is adequate for most patients. The maintenance dose should be adjusted appropriately at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and patient response, and may be increased to a maximum of 20 milligrams per day. 3. Elderly patients: No dose adjustment is necessary. 4. Patients with renal impairment: No dose adjustment is necessary for patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering this medicine at 20mg to patients with moderate renal impairment. 5. Patients with hepatic impairment: Systemic exposure to rosuvastatin did not increase in patients with a Child-Pugh score of 7 or less, but increased in patients with a Child-Pugh score of 8 or 9. Renal function tests should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score above 9. Do not administer this medicine to patients with active liver disease. 6. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40 milligram dose is contraindicated. 7. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40 milligram dose is contraindicated in some of these patients.

Child dose

Ages 10 to 17 years: The usual dose range is 5 milligrams to 20 milligrams once daily. (There are no clinical data on doses higher than 20 milligrams in pediatric patients.) The dose should be adjusted individually according to the recommended treatment goal for each patient. The dose should be adjusted at intervals of 4 weeks or longer. Under 10 years of age: Safety and efficacy have not been established.

Precautions

This medication should not be taken by certain patients. For instance, individuals with an allergy to this medication, patients with severe liver dysfunction, muscular disorders, severe renal impairment, or women who are pregnant or breastfeeding should avoid using it. Additionally, this drug may cause muscle-related side effects, so caution should be exercised for patients who are at higher risk for myalgia or myopathy. In particular, dosage adjustments should be considered for patients with moderate to severe renal impairment, hypothyroidism, a family history of such disorders, individuals with a history of alcohol abuse, specific ethnic groups (Asian patients), and those taking fibrate drugs. This medication contains lactose, so individuals with lactose intolerance or related genetic conditions should not take it. Moreover, patients sensitive to yellow dye (Yellow No. 5) should use it cautiously. Patients with poor liver function or those who consume excessive alcohol should have liver function tests before taking this medication and have their liver enzyme levels monitored regularly. It is advisable for patients with hypercholesterolemia due to hypothyroidism or certain nephrotic syndromes to receive treatment for the underlying condition before using this medication. If symptoms such as muscle pain, muscle weakness, cramps, fatigue, or fever occur during treatment, medical attention should be sought immediately, and blood tests may be needed to check for muscle damage. In severe cases, discontinuation of therapy may be required, and if symptoms improve, re-initiation at a lower dose may be considered. This medication interacts with certain other medications, so patients taking other drugs must inform their doctor or pharmacist. In particular, co-administration with cyclosporine, fibrate-class drugs, niacin, and certain antibiotics and antifungals may increase the risk of muscle side effects. Women who are pregnant or may become pregnant should use appropriate contraception and discontinue use immediately if they become pregnant. Breastfeeding women should also avoid using this medication for safety. In case of overdose, as there is no specific antidote, treatment should be symptomatic, and liver function and muscle enzyme levels should be monitored. This drug does not significantly affect driving or operating machinery; however, caution is needed as symptoms such as dizziness may occur. Finally, this medication may rarely cause serious skin reactions, liver damage, kidney issues, or muscular diseases; thus, if unusual symptoms arise, consultation with medical personnel should be sought immediately.

Side effects

Hypersensitivity reactions including angioedema, diabetes, headache, dizziness, constipation, nausea, abdominal pain, pancreatitis, pruritus, rash, urticaria, myalgia, myopathy, rhabdomyolysis, asthenia, polyneuropathy, amnesia, peripheral neuropathy, severe myasthenia gravis, cough, dyspnea, diarrhea, ocular myasthenia, thrombocytopenia, jaundice, hepatitis, increased transaminases, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms, lichenoid drug eruption, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive impairment, increased ALT, chest pain, muscle cramps, gout, erectile dysfunction, increased AST, joint pain, fatigue, numbness, paresthesia, chest discomfort, anorexia, abdominal distension, abnormal liver function tests, syncope, widespread pain

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be kept in a tightly sealed container to prevent exposure to air and moisture. It is best stored at a temperature between 1 to 30 degrees Celsius.

Appearance and packaging

Appearance

Pink, round film-coated tablets

Package unit

30 tablets (15 tablets/PTP x 2), 30 tablets/bottle, 100 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.